Levente Meszaros
Corporate Officer/Principal bei RADIOPHARM THERANOSTICS LIMITED
Aktive Positionen von Levente Meszaros
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Corporate Officer/Principal | 01.01.2022 | - |
NanoMab Technology Ltd.
 NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Karriereverlauf von Levente Meszaros
Statistik
International
| China | 2 |
| Australien | 2 |
Operativ
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 2 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Health Services |
| Private Unternehmen | 1 |
|---|---|
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | Health Technology |
- Börse
- Insiders
- Levente Meszaros
- Erfahrung